The Growth Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Growth Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Growth Disorders. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Growth Disorders and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Growth Disorders by 15 companies/universities/institutes. The top development phase for Growth Disorders is preclinical with six drugs in that stage. The Growth Disorders pipeline has 16 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Growth Disorders pipeline products market are: Kexing Biopharm, Polus and Junhemeng Biopharmaceutical (Hangzhou).
The key targets in the Growth Disorders pipeline products market include Growth Hormone Receptor (Somatotropin Receptor or GHR), Atrial Natriuretic Peptide Receptor 2 (Atrial Natriuretic Peptide Receptor Type B or Guanylate Cyclase B or NPR2 or EC 4.6.1.2), and Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR).
The key mechanisms of action in the Growth Disorders pipeline product include Growth Hormone Receptor (Somatotropin Receptor or GHR) Agonist with nine drugs in Pre-Registration. The Growth Disorders pipeline products include four routes of administration with the top ROA being Subcutaneous and five key molecule types in the Growth Disorders pipeline products market including Recombinant Protein, and Small Molecule.
Growth Disorders overview
Growth disorders are problems that prevent children from developing normal height, weight, sexual maturity or other features. Very slow or very fast growth can sometimes signal a gland problem or disease. The pituitary gland makes growth hormone, which stimulates the growth of bone and other tissues. Children who have too little of it may be very short. Treatment with growth hormone can stimulate growth.
For a complete picture of Growth Disorders’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
